Document Detail


The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential.
MedLine Citation:
PMID:  24965547     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Technology often serves as a handmaiden and catalyst of invention. The discovery of safe, effective medications depends critically upon experimental approaches capable of providing high-impact information on the biological effects of drug candidates early in the discovery pipeline. This information can enable reliable lead identification, pharmacological compound differentiation and successful translation of research output into clinically useful therapeutics. The shallow preclinical profiling of candidate compounds promulgates a minimalistic understanding of their biological effects and undermines the level of value creation necessary for finding quality leads worth moving forward within the development pipeline with efficiency and prognostic reliability sufficient to help remediate the current pharma-industry productivity drought. Three specific technologies discussed herein, in addition to experimental areas intimately associated with contemporary drug discovery, appear to hold particular promise for strengthening the preclinical valuation of drug candidates by deepening lead characterization. These are: i) hydrogen-deuterium exchange mass spectrometry for characterizing structural and ligand-interaction dynamics of disease-relevant proteins; ii) activity-based chemoproteomics for profiling the functional diversity of mammalian proteomes; and iii) nuclease-mediated precision gene editing for developing more translatable cellular and in vivo models of human diseases. When applied in an informed manner congruent with the clinical understanding of disease processes, technologies such as these that span levels of biological organization can serve as valuable enablers of drug discovery and potentially contribute to reducing the current, unacceptably high rates of compound clinical failure.
Authors:
David R Janero
Related Documents :
1621007 - The next generation: new chemotherapy agents for the 1990s.
23786507 - Characteristics of alprazolam-related deaths compiled by a centralized state medical ex...
10308117 - New prescription for drug regulation.
23115047 - Overcoming obstacles in parkinson's disease.
15542077 - Evaluation of the tail formalin test in mice as a new model to assess local analgesic e...
21359537 - Risk factors associated with dress syndrome produced by aromatic and non-aromatic antip...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-6-26
Journal Detail:
Title:  Expert opinion on drug discovery     Volume:  -     ISSN:  1746-045X     ISO Abbreviation:  Expert Opin Drug Discov     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-6-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101295755     Medline TA:  Expert Opin Drug Discov     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1-12     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Clinical and Nutritional Comparison of Biliopancreatic Diversion Performed with Different Common a...
Next Document:  Parental mental illness and eating disorders in offspring.